Loading
Latest filing published 01 Jul 2024 for Gain Therapeutics, Inc., €5,728. Read the official filing
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Eric I. Richman (chief executive) discloses dealings in 2 companies, chiefly Gain Therapeutics, Inc. and Ohr Pharmaceutical Inc. The record holds 7 filings, for trades running from 16 August 2021 to 1 July 2024.
On the market, this insider has only ever bought: 5 purchases, €57k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 option exercises. 2024 to date brings 1 purchase and no sales.
Half of the purchases are above €5,992 and half below. Of 4 purchases, 2 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
On 1 July 2024 came the latest disclosure, an open-market purchase for €5,728 in Gain Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations